|
gptkbp:instanceOf
|
antidepressant
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
N06AA02
|
|
gptkbp:brand
|
gptkb:Tofranil
|
|
gptkbp:CASNumber
|
50-49-7
|
|
gptkbp:category
|
gptkb:dibenzazepine
antidepressant
tertiary amine
norepinephrine reuptake inhibitor
tricyclic compound
|
|
gptkbp:chemicalFormula
|
C19H24N2
|
|
gptkbp:contraindication
|
recent myocardial infarction
concurrent MAOI use
|
|
gptkbp:discoveredBy
|
gptkb:Geigy
|
|
gptkbp:eliminationHalfLife
|
11–25 hours
|
|
gptkbp:firstSynthesized
|
1948
|
|
gptkbp:has_metabolite
|
gptkb:desipramine
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
imipramine
|
|
gptkbp:introduced
|
1957
|
|
gptkbp:IUPACName
|
3-(10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine
|
|
gptkbp:KEGGID
|
D00177
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
norepinephrine reuptake inhibitor
|
|
gptkbp:meltingPoint
|
167–168 °C
|
|
gptkbp:MeSH_ID
|
D007090
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
280.41 g/mol
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:proteinBinding
|
60–96%
|
|
gptkbp:PubChem_CID
|
3696
DB00458
CHEMBL48
|
|
gptkbp:riskFactor
|
gptkb:orthostatic_hypotension
seizures
QT prolongation
anticholinergic effects
overdose toxicity
|
|
gptkbp:routeOfAdministration
|
oral
intramuscular
|
|
gptkbp:sideEffect
|
constipation
weight gain
drowsiness
dry mouth
sexual dysfunction
|
|
gptkbp:solubility
|
slightly soluble in water
|
|
gptkbp:UNII
|
7BB9YJ8U49
|
|
gptkbp:usedFor
|
gptkb:depression
anxiety disorders
enuresis
|
|
gptkbp:bfsParent
|
gptkb:CYP3A4
|
|
gptkbp:bfsLayer
|
5
|